Mapping the cerebral monoamine oxidase type A: Positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 467-473

  Bottlaender, Michel ^a,c   Dollé, Frédéric ^a   Guenther, Ilonka ^a   Roumenov, Dimitri ^a   Fuseau, Chantal ^a   Bramoulle, Yann ^a   Curet, Olivier ^b   Jegham, Jamir ^b   Pinquier, Jean Louis ^b   George, Pascal ^b   Valette, Heric ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b SANOFI   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BEFLOXATONE; BRAIN MONOAMINE; CARBON 11; LAZABEMIDE; LIGAND; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BINDING SITE; DRUG BRAIN LEVEL; DRUG SELECTIVITY; DRUG UPTAKE; ENZYME LOCALIZATION; INJECTION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; THALAMUS;

ANIMALS; BIOTRANSFORMATION; BRAIN; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXAZOLES; PAPIO; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037405749     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.046953     Document Type: Article

References (38)

1. 11C]brofaromine, a potential tracer for imaging monoamine oxidase A. Nucl Med Biol 23:229-234.
2. Banknieder AR, Phillips JM, Jackson KT, and Vinal SI (1978) Comparison of ketamine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulata). Lab Anim Sci 28:742-745.
3. Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, et al. (1991) Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 40:173.
4. Bendriem B (1991) Quantitative evaluation of a new brain tomograph the ECAT 953B/31. J Nucl Med 32:1063-1991.
5. 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol 24:381-388.
6. 11C-Harmine as a tracer for monoamine oxidasse A (MAO-A): In vitro and in vivo studies. Nucl Med Biol 24:287-293.
7. Bergström M, Westerberg G, Németh G, Traut M, Gross G, Greger G, Müller-Peltzer H, Safer A, Eckernäs S-A, and Grahner A (1997c) MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur J Clin Pharmacol 52:121-128.
8. Berlin I, Saïd S, Spreux-Varoquaux O, Launay J-M, Olivares R, Millet V, Lecrubier Y, and Puech A (1995) A reversible monoamine oxidase A inhibitor (moclobrmide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 58:444-452.
9. Brouillet E, Chavoix C, Khalili-Varasteh M, Bottlaender M, Hantraye Ph, Yorke J-C, and Mazière M (1990) Quantitative evaluation of benzodiazepine receptors in live Papio papio baboons using positron emission tomography. Mol Pharmacol 38:445-451.
10. Brunner HG, Nelen M, Breakefield XO, Ropers HH, and Van Oost BA (1993) Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science (Wash DC) 262:578-580.
11. Caille D, Bergis O-E, Fankhausser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, and Jarreau F-X (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 277:265-277.
12. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, and Jarreau F-X (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277:253-264.
13. Curet O, Damoiseau G, Labaune J-P, Rovei V, and Jarreau F-X (1994) Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. J Neural Transm 41:349-355.
14. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, and Haefely W (1998) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400-412.
15. 11C]Befloxatone, a novel highly potent radioligand for in vivo imaging mono-amine oxidase-A. J Labelled Compd Radiopharm 42:608-609.
16. 11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A. Bioorg Med Chem Lett, in press.
17. 11C]clorgyline binding in brain. Nucl Med Biol 28:779-785.
18. 11C-labeled suicide inactivators and PET. Science (Wash DC) 235:481-485.
19. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor RR, Alexoff DL, Shea C, Schlyer D, Wolf AP, et al. (1996a) Inhibition of monoamine oxidase B in the brains of smokers. Nature (Lond) 379:733-736.
20. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, Shea C, Alexoff DL, MacGregor RR, Schlyer D, Zezulkova I, and Wolf AP (1996b) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93:14065-14069.
21. Fowler JS, Wang G-J, Volkow ND, Logan J, Franceschi D, Franceschi M, MacGregor RR, Shea C, Garza V, Liu N, and Ding YS (2000) Evidence that gingko biloba extract does not inhibit MAO-A and B in living human brain. Life Sci 66:PL141-P146.
22. Haefely W, Kettler R, Keller HH, and Da Prada M (1990) Ro 19-6327, a reversible and highly selective monoamine oxidase B inhibitor: a novel tool to explore the MAO-B function in humans, in Parkinson's Disease: Anatomy, Pathology, and Therapy (Streifler MB, Korczyn AD, Melamed E, and Youdim MBH eds) pp 505-512, Raven Press, New York.
23. Landais P and Crouzel C (1987) A new synthesis of carbon-11 labelled phosgene. Appl Radiat Isot 38:297-300.
24. 11C]labelled phosgene. J Label Compds Radiopharm 40:306-308.
25. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
26. Luque JM, Bleuel Z, Hendrickson A, and Richards JG (1996) Detection of MAO-A and MAO-B mRNAs in monkey brainstem by cross-hybridization with human oligonucleotide probes. Mol Brain Res 36:357-360.
27. 3H]harman binding and monoamine oxidase subtypes A and B activity in Marmoset and rat. J Neurochem 56:500-508.
28. 11C)-Ro15-1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by positron emission tomography. J Cereb Blood Flow Metab 8:304-313.
29. Pappata S, Tavitian B, Traykov L, Jobert A, Dalger A, Mangin JF, Crouzel C, and DiGiamberardino L (1996) In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 67:876-879.
30. 11C]Ro15-1788 binding to the human neocortex using positron emission tomography. Human Psychopharmacol 4:21-31.
31. Rosenzweig P, Patat A, Curet O, Durrieu G, Dubruc C, Zieleniuk I, and Legangneux E (1998) Clinical pharmacology of befloxatone: a brief review. J Affect Disord 51:305-312.
32. Rovei V, Caille D, Curet O, Ego D, and Jarreau F-X (1994) Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. J Neural Transm 41:339-347.
33. 3H-Ro19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs and human brain. J Neurosci 12:1977-1999.
34. Saura J, Nadal E, van den Berg B, Vila M, Bombi JA, and Mahy N (1996) Localization of monoamine oxidases in human peripheral tissues. Life Sci 59:1341-1349.
35. Westlund KN, Denney RM, Kochersperger LM, Rose RM, and Abell CW (1985) Distinct monoamine oxidase A and B population in primate brain. Science (Wash DC) 230:181-183.
36. Westlund KN, Denney RM, Rose RM, and Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell population in human brainstem. Neurosci 25:439-456.
37. Willoughby J, Glover V, and Sandler M (1988) Histochemical localisation of monoamine oxidase A and B in rat brain. J Neural Transm 74:29-42.
38. Wouters J, Moureau F, Evrard G, Koenig J-J, Jegham S, George P, and Durant F (1999) A reversible monoamine oxidase a inhibitor, befloxatone: structural approach of its mechamism of action. Bioorg Med Chem 7:1683-1693.